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INTRODUCTION
Mucopolysaccharidosis II (MPS II, Hunter syndrome; OMIM 
309900) is an X-linked lysosomal storage disease caused by a 
deficiency in the enzyme iduronate-2-sulfatase (I2S), which 
is required for the catabolism of glycosaminoglycans (GAG).1 
Accumulation of GAG in cells, tissues, and organs produces 
multi-systemic, progressive disease.2,3 Approximately two-
thirds of patients have the severe phenotype, characterized by 
progressive cognitive decline.4
Weekly infusions of idursulfase, recombinant human I2S 
(Elaprase, Shire, Lexington, MA), have been shown to improve 
some somatic manifestations in MPS II patients,5,6 but the 
enzyme does not penetrate the blood–brain barrier at therapeu-
tic doses or alter cognitive decline in severe disease.7 Animal 
studies have demonstrated that intrathecally administered idur-
sulfase can penetrate into brain tissue.8 Therefore, the present 
phase I/II trial (NCT00920647) studied the direct administra-
tion of investigational recombinant I2S into the cerebrospinal 
fluid (CSF) as a means of delivering the drug to the central 
nervous system (CNS). The investigational product, idursul-
fase-IT, is a formulation of recombinant human I2S for intra-
thecal (IT) administration into CSF using an IT drug delivery 
device (IDDD). The primary study objective was to determine 
the safety and tolerability of ascending doses of idursulfase-IT 
administered via IDDD once monthly for 6 months to MPS 
II patients with cognitive impairment who were concurrently 
receiving intravenous (i.v.) idursulfase. This novel approach is 
supported by existing knowledge of the leptomeningeal space 
and molecule transfer from CSF into the brain parenchyma.8,9
MATERIALS AND METHODS
Patients
Patients with MPS II were recruited between June 2009 
and March 2012 and enrolled at the University of North 
Carolina-Chapel Hill, Chapel Hill, North Carolina, USA, and 
Birmingham Children’s Hospital, Birmingham, UK. Included 
patients were males who were between 3 and 18 years of age 
who tolerated ≥6 months of treatment with 0.5 mg/kg weekly 
i.v. idursulfase before screening. Included patients had evi-
dence of MPS II–related cognitive impairment on formal neu-
rodevelopmental assessment at screening. Initially, cognitive 
impairment was defined as an overall intelligence quotient (IQ) 
that was ≥2 but ≤3 SDs below the mean of the healthy popula-
tion. Alternatively, a decline of at least 1 SD in IQ score was 
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Purpose: Approximately two-thirds of patients with the lysosomal 
storage disease mucopolysaccharidosis II have progressive cognitive 
impairment. Intravenous (i.v.) enzyme replacement therapy does 
not affect cognitive impairment because recombinant iduronate-2- 
sulfatase (idursulfase) does not penetrate the blood–brain barrier at 
therapeutic concentrations. We examined the safety of idursulfase for-
mulated for intrathecal administration (idursulfase-IT) via intrathecal 
drug delivery device (IDDD). A secondary endpoint was change in 
concentration of glycosaminoglycans in cerebrospinal fluid.
Methods: Sixteen cognitively impaired males with mucopolysacchari-
dosis II who were previously treated with weekly i.v.  idursulfase 0.5 mg/
kg for ≥6 months were enrolled. Patients were randomized to no treat-
ment or 10-mg, 30-mg, or 1-mg idursulfase-IT monthly for 6 months 
(four patients per group) while continuing i.v. idursulfase weekly.
Results: No serious adverse events related to idursulfase-IT were 
observed. Surgical revision/removal of the IDDD was required in 6 of 
12 patients. Twelve total doses were administrated by lumbar punc-
ture. Mean cerebrospinal fluid glycosaminoglycan concentration was 
reduced by approximately 90% in the 10-mg and 30-mg groups and 
approximately 80% in the 1-mg group after 6 months.
Conclusions: These preliminary data support further development 
of investigational idursulfase-IT in MPS II patients with the severe 
phenotype who have progressed only to a mild-to-moderate level of 
cognitive impairment.
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permitted as evidence of cognitive impairment, provided the 
patient’s IQ remained ≤3 SD from the mean of the healthy pop-
ulation.10,11 Because of difficulties with initial enrollment with 
these cognitive impairment criteria, and given that the primary 
endpoint of the study was safety and tolerability, these criteria 
were amended in the protocol several times over the course 
of the study. The final inclusion criteria for cognitive impair-
ment were an IQ score ≤77 points or evidence of an IQ score 
decline of ≥1 SD (15 IQ points) but ≤2 SD (30 IQ points) from 
a previous neurodevelopmental assessment, with a duration of 
neurologic involvement between 3 and 36 months. During the 
course of the trial, all patients met the first of the final inclusion 
criterion for cognitive impairment (IQ score ≤77 points); no 
patient was actually enrolled by means of the second of the final 
inclusion criteria (IQ score decline).
Exclusion criteria included the following: clinically signifi-
cant CNS involvement unrelated to MPS II; opening CSF pres-
sure >30.0 cm of H2O; CNS shunt; poorly controlled seizure 
disorder; hematopoietic stem cell transplantation; blood prod-
uct transfusions within 90 days of screening; and skeletomus-
cular/spinal abnormalities or other contraindications for the 
surgical implantation of the IDDD.
Investigational product and intrathecal drug delivery 
device
Idursulfase-IT is a sterile, isotonic solution of recombinant 
human I2S manufactured in single-use vials for IT administra-
tion via an indwelling IDDD (PORT-A-CATH II Low Profile 
Intrathecal Implantable Access System; Smiths Medical, St. 
Paul, MN). The dosing solution was provided at 50 mg/ml 
and diluted as needed in preservative-free saline. The IDDD 
implant was performed according to the instructions for use, 
with a lumbar incision to allow for the insertion of the catheter 
at the level of L4–L5 and a second incision on the lower ribs to 
allow for the implant of the access port. The catheter tip was 
threaded up the spinal canal to the mid-thoracic level. During 
access, ~7 ml of CSF was removed. The first milliliter was dis-
carded, with the subsequent volume divided into aliquots for 
analysis. A flush of ≥2 ml of preservative-free saline was rec-
ommended after the dose was administered, but typically addi-
tional saline was flushed to compensate for the total volume of 
CSF withdrawn. The process of drug administration and flush 
by slow bolus took ~2–5 min.
Study design
The study was a randomized, open-label study approved 
by the relevant institutional review boards and conducted 
in compliance with the Declaration of Helsinki, relevant 
institutional review board regulations, and International 
Conference on Harmonisation Good Clinical Practice 
guidelines. A placebo control was not considered because 
of an unacceptable risk/benefit ratio associated with IDDD 
placement and IT administration of an inactive compara-
tor. Written informed consent was obtained from parents or 
legal guardians.
Prospectively generated permuted block randomization12 
using four blocks of size four each and an allocation ratio of 
3:1 within each block (treatment:no treatment) was used to 
create three dose cohorts of five to six patients each. In each 
dose cohort, four patients were randomized to IDDD implanta-
tion plus administration of idursulfase-IT once monthly (every 
28 ± 7 days) for 6 months, and in each dose cohort one or two 
patients were randomized to no treatment. Those randomized 
to treatment in the first, second, and third cohorts received 
10-mg, 30-mg, and 1-mg idursulfase-IT monthly, respectively. 
In total, 16 patients were randomized—four IT-treated patients 
per dose group and four patients in the no treatment group.
The IDDDs were implanted in treated patients at week 1, 
followed by 2 weeks of recovery. The first dose of idursulfase-
IT was given at week 3. CSF samples were drawn immediately 
before administration of each idursulfase-IT dose. For the first 
four doses, idursulfase-IT was administered only after CSF 
analysis confirmed a white blood cell (WBC) count <30 WBC/
mm3, requiring ~20–40 min between CSF sampling and dose 
administration. If the IDDD became nonfunctional or its use 
was precluded, then CSF sampling and/or dosing by lumbar 
puncture were permitted.
The original dose-escalation study design specified the eval-
uation of idursulfase-IT at dose levels of 10, 30, and 100 mg. 
After preliminary data showed a similar pharmacodynamic 
response in both the 10-mg and 30-mg groups, the protocol 
was amended, replacing the 100-mg dose with a 1-mg dose. 
Therefore, we present our findings here in order of the 10-mg, 
30-mg, and 1-mg groups to reflect the protocol change.
All patients continued to receive 0.5 mg/kg i.v. idursulfase 
weekly. At least 48 hours elapsed between idursulfase-IT dos-
ing and subsequent i.v. idursulfase dosing.
Endpoints and assessments
The primary endpoint was safety and tolerability. Assessments 
included adverse events (AEs), 12-lead electrocardiogram 
(ECG) findings, complete blood count, serum chemistries, CSF 
glucose, protein, red blood cell count and WBC count includ-
ing a differential, and anti-I2S antibodies in CSF and serum. 
Treatment-emergent adverse events (TEAEs) were defined 
as all AEs occurring between the time of randomization and 
the last follow-up contact at 30 ± 7 days after the end of this 
6-month study. All eligible patients continued on to the exten-
sion study, the results of which will be reported separately. 
TEAEs were graded for severity from mild (grade 1) to death 
(grade 5).13 Serious adverse events (SAEs) were any TEAEs that 
were life-threatening or resulted in death, inpatient hospitaliza-
tion, prolongation of existing hospitalization, or persistent or 
significant disability/incapacity.
All antibody testing was performed by a Shire-designated 
contract research organization (Pharmaceutical Product 
Development, LLC, Richmond, VA). Anti-I2S antibodies were 
detected by a bridging electrochemiluminescent immunoassay 
using the Meso Scale Discovery technology platform (Meso 
Scale Diagnostics, LLC, Rockville, MD). Biotin-idursulfase 
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was used as the capture reagent, and sulfo-tagged idursulfase 
was used as the detection reagent. Positive samples were con-
firmed by ligand-competition assay and then further tested 
for the antibody titer and neutralizing activity. Neutralizing 
activity was detected by an I2S enzymatic activity assay using 
4-methylumbelliferyl-sulfate as substrate. Titer was defined as 
the reciprocal of the highest sample dilution (including mini-
mum required dilution) with a positive result.
The study’s secondary endpoints, summarized by dose group, 
included pharmacokinetic parameters of I2S in serum and CSF 
after the administration of idursulfase-IT and the change in CSF 
and urinary GAG concentrations from baseline. The quantifica-
tion of I2S in serum and CSF was performed by Shire using an 
enzyme-linked immunosorbent assay as previously described.14 
The quantification of total CSF GAG concentration was deter-
mined by Shire using a thrombin activity assay with chromogenic 
substrate S-2238 (Chromogenix, Bedford, MA). CSF samples 
were pre-incubated with a fixed amount of human heparin cofac-
tor II (Haematologic Technologies, Essex Junction, VT), then 
incubated with a fixed amount of human α-thrombin (Enzyme 
Research Laboratories, South Bend, IN) and 0.5 mmol/l S-2238 
in assay buffer. GAG in CSF samples binds to heparin cofactor 
II, which in turn accelerates thrombin inactivation. The GAG 
concentration in CSF samples was calculated from a calibration 
curve prepared from dermatan sulfate (GAG-DS01, Iduron, 
Manchester, UK) included in the same assay. The quantifica-
tion of urinary GAG was performed by Cambridge Biomedical 
(Boston, MA) using a Blyscan Glycosaminoglycan Assay kit 
(Biocolor Life Science Assays, Carrickfergus, UK), and results 
were normalized to urine creatinine.
Blood samples for pharmacokinetic assessments were drawn 
at week 3 (first idursulfase-IT dose) and week 23 (last idursul-
fase-IT dose). For the analysis of the serum enzyme pharma-
cokinetics after intrathecal administration of idursulfase-IT, 
blood samples were initially drawn within 15 min before idur-
sulfase-IT administration (pre-injection baseline), and then at 
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after administration. 
Later, time points of 30 and 36 hours after administration were 
added by protocol amendment because early data indicated that 
the appearance of enzyme in serum was slow and maintained. 
To analyze serum pharmacokinetics after i.v. administration of 
idursulfase, blood samples were drawn at pre-infusion baseline, 
then at 0.5, 1, 1.5, 2, 2.5, and 3 hours during the infusion, and at 
3.5, 4, 5, 6, 7, 9, 11, and 24 hours after the infusion. CSF samples 
from treated patients were collected via IDDD or lumbar punc-
ture immediately before each administration of idursulfase-IT 
and at week 27 (30 ± 7 days after the sixth dose of idursulfase-
IT). For patients assigned to no treatment, CSF samples were 
collected via lumbar puncture at screening and week 27. Urine 
samples were collected up to 24 hours before each administra-
tion of idursulfase-IT and at week 27 (30 ± 7 days after the sixth 
dose of idursulfase-IT) for treated patients, and at screening 
and week 27 for no treatment patients.
Data from the intent-to-treat group, comprising all random-
ized patients, were used in all data analyses. Data analyses were 




Demographics and baseline characteristics are provided in 
Table 1.
Treatment exposure
Seven of 12 treated patients (58.3%) received all scheduled 
doses of idursulfase-IT, either by IDDD or by lumbar puncture. 
Four patients (33.3%), two each in the 1-mg and 30-mg groups, 
received five of six scheduled doses, and one patient (8.3%) in 
the 30-mg group received four of six scheduled doses. Device 
malfunction led to partial revision, total surgical revision, or 
removal in 6 of 12 (50%) treated patients (Figure 1).
Safety assessments
Treatment with idursulfase-IT appeared generally well- 
tolerated (Table 2). There were no deaths or discontinuations. 
Most TEAEs were mild to moderate (grades 1–2) in sever-
ity. There were six severe (grade 3) events experienced by 
three patients, one in each dose group. These included device 
breakage, device dislocation, complication of device inser-
tion/orientation, procedure complication, and implant site 
infection. There was no evidence of increasing TEAE severity 
or frequency with higher doses of idursulfase-IT. There were 
34 TEAEs that were assessed as possibly/probably related to 
idursulfase-IT. Most of these fell into the “investigations” cat-
egory, such as blood pressure and heart rate abnormalities, 
or an increased CSF protein level. Others included behavior 
change, vomiting, nausea, pyrexia, erythema, anxiety, and 
pyramidal tract syndrome.
Fourteen SAEs were experienced by 7 of 12 (58.3%) treated 
patients (Table 2). All SAEs were so designated because hospi-
talization was required. Notably, 12 of 14 (85.7%) SAEs were 
IDDD-related (complication of device insertion, device dislo-
cation/connection issue, device breakage/malfunction/failure, 
implant site infection, procedural pain, and wound dehis-
cence). The other two (vomiting and dehydration) were expe-
rienced by a patient who was implanted with an IDDD but had 
not yet received study drug. No SAEs were reported in the no 
treatment group.
There were no clinically meaningful changes from baseline in 
serum chemistry, hematology, urinalysis laboratory values, CSF 
laboratory values, or ECG findings over time (data not shown). 
There were no important differences between treated and 
untreated patients or between the 1-mg, 10-mg, or 30-mg dose 
groups. CSF WBC count was monitored throughout the study, 
and no evidence was found to suggest any association between 
CNS inflammation and idursulfase-IT. Occasional instances of 
transient, asymptomatic CSF leukocytosis (maximum value, 
33 WBC/mm3) were noted and typically preceded IDDD fail-
ures, sometimes by several months. All episodes resolved either 
spontaneously or after device revision/removal.
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Immunogenicity in serum
Seven of 15 evaluated patients (47%) tested anti-I2S antibody 
positive in serum at week 3 (measurements were taken before 
IT dosing for treated patients). Note that all enrolled patients 
in this study had received i.v. idursulfase for ≥6 months before 
study entry and continued receiving it throughout the study. 
Of the seven patients with serum antibody positivity at week 
3, six patients had stable antibody titers (within ±1 step of a 
1:4 serial dilution) throughout the study. The seventh patient, 
in the 10-mg group, showed a generally decreased serum anti-
body titer over time and tested antibody–negative at week 27. 
An eighth patient, from the no treatment group, was serum 
antibody–negative at baseline but tested positive at week 27.
Of the eight patients who were serum antibody–positive at 
any point, two patients in the 1-mg group and one patient in 
the no treatment group had substantial neutralizing antibody 
activity (neutralizing antibody titer ≥800) that remained stable 
throughout the study. Weak neutralizing activity (neutralizing 
antibody titer <800) was seen at least once during the study for 
three of eight antibody-positive patients, one from each idursul-
fase-IT dose group. The remaining two patients, both in the no 
treatment group, had no detectable neutralizing antibody activ-
ity at any time during the study.
Immunogenicity in cerebrospinal fluid
Before the first exposure to idursulfase-IT, anti-I2S antibodies 
were detected in CSF for 6 of 15 patients (40%). The observed 
CSF antibody titers appeared largely stable (within ±2 steps of 
a 1:2 serial dilution) throughout the study. The corresponding 
serum samples for these six patients also tested antibody-posi-
tive; serum antibody titers were typically much higher relative 
to the corresponding CSF antibody titers. The highest titers 
were observed in patient 12 (1-mg group), who had a large 
deletion in the I2S gene and who had a serum antibody titer 
of 655,360 and CSF antibody titer of 5,120 before idursulfase-
IT exposure. He had the least pronounced CSF GAG response 
(Figure 3).
Of the patients who had no CSF antibodies to idursulfase at 
study start, none subsequently developed them. One patient in 
the no treatment group did not have sufficient CSF volume at 
baseline for immunogenicity testing but was antibody-nega-
tive in the CSF at week 27.
Table 1 Summary of patient demographic and baseline characteristics
Baseline characteristics No Treatment (n = 4)
Idursulfase-IT 
10 mg (n = 4)
Idursulfase-IT 




  N 4 4 4 4
  Mean 8.6 4.3 6.9 5.6
  SD 2.5 0.8 1.7 1.8
  Median (min, max) 8.9 (5.5, 11.2) 4.1 (3.6, 5.5) 7.1 (4.8, 8.8) 4.9 (4.5, 8.3)
Race (n (%))
  Asian 0 0 1 (25.0) 0
  White 3 (75.0) 3 (75.0) 3 (75.0) 2 (50.0)
  Other 1 (25.0) 1 (25.0) 0 2 (50.0)
Ethnicity (n (%))
  Hispanic or Latino 1 (25.0) 0 0 0
  Not Hispanic or Latino 3 (75.0) 3 (75.0) 3 (75.0) 4 (100.0)
  Not reported 0 1 (25.0) 1 (25.0) 0
Country (n (%))
  United Kingdom 1 (25.0) 0 2 (50.0) 2 (50.0)
  United States 3 (75.0) 4 (100.0) 2 (50.0) 2 (50.0)
Height (cm)
  N 4 4 4 4
  Mean 122.5 107.5 123.6 115.5
  SD 12.7 3.4 16.9 17.2
  Median (min, max) 118.0 (112.8, 141.1) 108.6 (102.4, 110.2) 129.2 (98.9, 137.0) 108.7 (103.5, 141.0)
Weight (kg)
  N 4 4 4 4
  Mean 35.4 20.7 33.4 29.1
  SD 8.2 2.3 10.2 11.8
  Median (min, max) 36.0 (26.6, 43.0) 20.0 (18.8, 24.1) 35.1 (19.4, 44.0) 24.1 (21.6, 46.7)
Baseline height and weight were defined as the screening assessment before the randomization date. If a screening measurement was not performed, then the closest prior 
measurement, including from a preceding screening study, was used as baseline.
IT, intrathecal; SD, standard deviation.
aAge at the randomization date.
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Pharmacokinetic parameters
After IT dosing, the 10-mg and 30-mg doses of idursulfase-IT 
exhibited similar serum I2S concentration-time profiles at week 
23 (Figure 2). Most patients had baseline I2S protein levels 
below the limit of quantitation, and only patients with detectable 
I2S protein levels are presented in Figure 2. Limited information 
exists on the serum pharmacokinetic profile of idursulfase-IT 
at the 1-mg dose. Only two of four patients in the 1-mg idur-
sulfase-IT group had serum I2S levels above the lower limit of 
quantitation, and only one of these had sufficient serum concen-
tration-time values to derive pharmacokinetic parameters.
Dose proportionality of serum I2S exposure was observed 
between the idursulfase-IT 1- and 10-mg groups for max-
imum observed serum concentration (Cmax) (7.9-fold 
Figure 1 Age, genotype, and overview of dosing and IDDD-related procedures. Implant refers to the implantation of an IDDD. Total revision refers to 
the removal and replacement of an IDDD in its entirety (i.e., both the access port and the catheter are removed and replaced). A partial revision refers to the 
removal and replacement of only the access port, with the original catheter remaining in situ. Removal refers to the removal of an IDDD in its entirety without 
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Dose via IDDD Dose via LP Skipped dose
Implant     Partial revision    Total revision Removal
Table 2 Overall summary of adverse events by treatment group
Description

























No AEs 0 —  0 —  0 —  0 —
At least one AE   4 (100.0) 23  4 (100.0) 116  4 (100.0) 104  4 (100.0) 147
At least one i.v. idursulfase 
infusion-related AE
1 (25.0) 1  4 (100.0)  14  2 (50.0)  7  2 (50.0)  9
At least one idursulfase-IT-related AE — —  3 (75.0)  7  3 (75.0)  11  3 (75.0)  16
At least one idursulfase-IT or i.v. 
idursulfase infusion-related AEa
— —  4 (100.0)  14  1 (25.0)  8  3 (75.0)  4
At least one severe (grade 3) AE 0 0  1 (25.0)  1  1 (25.0)  2  1 (25.0)  3
At least one life-threatening 
(grade 4) AE
0 0  0  0  0  0  0  0
At least one SAEb 0 0  2 (50.0)  3  2 (50.0)  3  3 (75.0)  8
Discontinued due to an AE 0 0  0  0  0  0  0  0
Deaths 0 0  0  0  0  0  0  0
AEs that occurred on or after the randomization date until the end-of -study visit date plus 30 days are TEAEs. Percentages of patients were based on the total number of 
intent-to-treat patients within each treatment group.
AE, adverse event; IT, intrathecal; i.v., intravenous; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
aThis category contains events that were considered related to either idursulfase-IT or i.v. idursulfase. Intravenous idursulfase was always administered at least 48 h after the 
dose of idursulfase-IT. bSAEs were defined as any AEs that were life-threatening or resulted in death, inpatient hospitalization, prolongation of existing hospitalization, or 
persistent or significant disability/incapacity.
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increase), but not area under the serum concentration-time 
curve (AUC0–last) (4.8-fold increase). Dose proportionality of 
serum I2S exposure was not observed between the idursul-
fase-IT 10-mg and 30-mg groups for Cmax or AUC0–last. The 
mechanism by which intrathecally administered idursulfase-
IT enters the systemic circulation is not clearly defined. One 
potential mechanism is that the protein is removed from the 
CSF through the arachnoid villi.15 Materials transverse the 
villi by micropinocytosis, which is a unidirectional process 
mediating transport from the CSF to the venous system or 
epidural space.
Systemic bioavailability for the 10-mg group was 44.4 ± 14.6% 
at week 3 and 46.8 ± 8.5% at week 23, resulting in mean equiva-
lent i.v. doses of 0.21 ± 0.08 mg/kg at week 3 and 0.22 ± 0.05 mg/
kg at week 23. Systemic bioavailability for the 30-mg group was 
22.3 ± 2.2% at week 3 and 22.2 ± 14.2% at week 23, resulting in 
mean equivalent i.v. doses of 0.23 ± 0.06 mg/kg at week 3 and 
0.21 ± 0.14 mg/kg at week 23. These observations suggest that 
bioavailability was consistent over time when the same dose of 
idursulfase-IT was administered, and that none of the patients 
received a systemic exposure from IT delivery of idursulfase-
IT that would be equivalent to the standard prescribed dose of 
0.5 mg/kg of i.v. idursulfase.
We determined the concentration of I2S in CSF prior to each 
idursulfase-IT dose (~30 days after the previous idursulfase-
IT dose). Monthly idursulfase-IT administration at doses of 
1–30 mg did not produce appreciable accumulation in the CSF 
(data not shown). Levels in the majority of samples were below 
the limit of quantification (3.13 ng/ml).
Glycosaminoglycan concentrations in cerebrospinal fluid 
and urine
Concentrations of GAG in CSF were evaluated as a marker 
for the biological activity of idursulfase-IT. CSF samples were 
obtained monthly, before the administration of idursulfase-IT. 
The observed GAG concentration at a given time point is that 
which is present 1 month after treatment. Because I2S is inac-
tive in physiological fluids, such as CSF,16 observed declines in 
CSF GAG after idursulfase-IT administration are likely attrib-
utable to reductions in GAG concentration in tissues rather 
than to direct enzymatic degradation of GAG in CSF.
At week 27, 30 ± 7 days after the final idursulfase-IT dose in 
this study, the mean concentration (±SE) of CSF GAG declined 
by 90 ± 3%, 89 ± 1%, and 79 ± 5% in the 10-mg, 30-mg, and 
1-mg groups, respectively. The major part of this decline was 
already apparent after the first dose of idursulfase-IT: 73 ± 7%; 
89 ± 1%; and 59 ± 10%, respectively. In the no treatment group, 
the mean concentration of CSF GAG (±SE) increased by 7 ± 6% 
by end of study. Individually, all treated patients experienced 
declines in CSF GAGs from baseline, whereas all no treatment 
patients had stable CSF GAG levels throughout (Figure 3). 
There was no apparent effect of idursulfase-IT on urinary GAG 
levels (data not shown).
DISCUSSION
Our primary objective was to investigate the safety of idursul-
fase-IT administered intrathecally once monthly to children with 
MPS II and cognitive impairment who were receiving concurrent 
i.v. idursulfase once weekly. Long-term neurocognitive data from 
this study and an extension study are forthcoming. Here, idursul-
fase-IT appeared generally well-tolerated. There was no appar-
ent relationship between the incidence or type of AEs and the 
dose. Although 7 of 12 treated patients experienced at least one 
SAE during the study, the majority (12/14) were related to IDDD 
malfunction. The issues associated with the device fell into two 
main categories: device breakage and catheter migration from 
the spinal canal. The high activity level in this pediatric popula-
tion may have contributed to the high rate of these AEs, because 
young patients with MPS II and cognitive impairment often have 
marked hyperactivity, impulsivity, and restlessness.17–19 A differ-
ent IDDD has been identified and implemented in subsequent 
studies of idursulfase-IT, to be described in future reports. Of 
note, there were no SAEs considered related to the study drug. 
There were no cases of infective meningitis. Administration of 
idursulfase-IT was also typically not associated with an elevated 
WBC count or other signs of CNS inflammation.
Idursulfase-IT did not appear to have high immunogenic 
potential after IT administration, although the brief 6-month 
Figure 2 Mean serum iduronate-2-sulfatase concentration-time 
profiles at week 23. Serum samples were taken from treated patients 
in each of the idursulfase-IT dosing groups following administration of 
idursulfase-IT (n values shown are per dose level), as well as following 
administration of intravenous (i.v.) idursulfase ~48 h later (n value is shown 
together, n = 9). These data are graphed together for comparative purposes. 
The level of iduronate-2-sulfatase protein in serum prior to idursulfase-IT 
administration (t = 0) was below the lower limit of quantification in 4/9 
patients; the mean value shown at t = 0 reflects only those samples with 
quantifiable amounts (n = 2 for the 10-mg group; n = 1 for the 30-mg group; 
and n = 2 for the 1-mg group, respectively). Similarly, the level of iduronate-
2-sulfatase in serum prior to i.v. idursulfase administration (t = 0) was below 
the lower limit of quantification in 7/9 patients; the mean value shown at 
t = 0 reflects only those samples with quantifiable amounts (n = 1 for the 
10-mg group; n = 1 for the 30-mg group; and n = 0 for the 1-mg group, 
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duration of the study and the small number of patients pre-
clude us from making firm conclusions in this regard. Six of 15 
patients (two in the no treatment group) had anti-I2S antibod-
ies in CSF before being exposed to idursulfase-IT. Their titers 
remained largely stable throughout the study, and no additional 
patients developed CSF antibodies during the study. These six 
patients also tested positive for serum antibodies, before any 
exposure to idursulfase-IT, at higher titers than those in CSF. 
This is entirely consistent with the previously published rates 
of antibody positivity in patients treated with idursulfase for ≥6 
months.5,14 The highest titers were observed in a patient with a 
large deletion in the I2S gene. Patients with a complete deletion 
produce no endogenous enzyme, probably causing idursulfase 
to be viewed as a non-self antigen. Because all patients had 
received ≥6 months of i.v. idursulfase therapy before enroll-
ment, the positive CSF antibody test results seen prior to 
idursulfase-IT exposure were likely due to movement of serum 
antibodies across the blood–brain barrier.20 Serum antibody 
titers also remained stable during the study. The only patient 
who developed serum antibodies during the study was in the 
no treatment group.
As a secondary endpoint, we assayed the concentration of 
CSF GAG over time. At week 27, the mean CSF GAG con-
centration declined by ~90% in the 10-mg and 30-mg groups 
Figure 3 Observed GAG concentrations in CSF for individual patients by scheduled study week visit and treatment group: (a) 10 mg, (b) 30 mg, (c) 1 mg, and 
(d) No-Treatment. CSF, cerebrospinal fluid; GAG, glycosaminoglycan.
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and ~80% in the 1-mg group. The decline was largely apparent 
after the first dose of idursulfase-IT. Because CSF samples were 
taken 1 month after the preceding drug dose, these results indi-
cate rapid and robust decreases in CSF GAG levels in response 
to idursulfase-IT that were sustained throughout the 6-month 
study. In contrast, the mean CSF GAG concentration for the 
no treatment group remained stable throughout. Although we 
have no direct evidence that idursulfase-IT, administered via 
IT bolus, penetrates the brain parenchyma in these patients, 
there are several indirect indications that this may be a reason-
able hypothesis. First, because recombinant I2S is inactive in 
the CSF, these data suggest that its pharmacodynamic activ-
ity takes place in lysosomes, which requires I2S uptake from 
the CSF into cells. Second, animal study data have shown that 
recombinant I2S penetrates into the brain parenchyma after 
either intraparenchymal administration to a mouse model 
of MPS II or IT administration to healthy monkeys.8 Third, 
idursulfase-IT is given as a bolus injection, followed by a flush 
of preservative-free saline, a procedure that may help drive 
the drug cephalad toward the brain.9 Fourth, MPS II patients 
often have dilated Virchov-Robin spaces, which may result in 
enhanced drug delivery to the brain parenchyma.9
In the pharmacokinetic analysis, we found a mean systemic 
bioavailability of 22–47% for idursulfase-IT at different doses, 
although limited information exists at the 1-mg dose. This was 
not unexpected, given the known clearance mechanisms for 
CSF.9 However, idursulfase-IT is not expected to supplant the 
need for weekly i.v. idursulfase to address certain somatic fea-
tures of MPS II, particularly as idursulfase-IT therapy is admin-
istered monthly, not weekly, and is not dosed based on weight. 
The bioavailability data support this expectation because the 
systemic exposure achieved in the 10-mg or 30-mg idursulfase-
IT groups was much less than that obtained after a 0.5-mg/kg 
dose of i.v. idursulfase.
In conclusion, monthly intrathecal administration of 
idursulfase-IT to patients with severe MPS II appeared to 
be generally well-tolerated in this small study and resulted 
in a >70% reduction in CSF GAG concentration 1 month 
after the first dose of 10 or 30 mg. The IDDD did not per-
form as anticipated in this active (and hyperactive) pediatric 
population, necessitating several surgical revisions/removals 
during the trial and triggering the adoption of a new IDDD 
for subsequent studies. Our conclusions should be inter-
preted with caution due to the small sample size of 12 treated 
patients and brief 6-month duration of treatment; however, 
the results support the continued development of idursul-
fase-IT as a potential therapy for the cognitive impairment 
of MPS II. An extension trial is ongoing to evaluate long-
term safety, immunogenicity, clinical, and cognitive out-
comes associated with idursulfase-IT treatment. In addition, 
a phase II/III study is recruiting children with severe MPS 
II who have progressed only to a mild to moderate level of 
cognitive impairment to determine the effect of monthly 
administration of idursulfase-IT on neurodevelopmental 
status over 12 months (NCT02055118).
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